Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc. | KT-621 - (BroADen2) | Atopic dermatitis | Phase 2b | Ongoing | Intravenous | Immunology |
| Kymera Therapeutics Inc. | KT-474 (SAR444656) - (ADVANTA) | Hidradenitis suppurativa / atopic dermatitis | Phase 2 | Trial Discontinued | oral | Immunology |
| Kyntra Bio Inc Com (New) | Roxadustat - (China trial) | Anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies | NDA Filing | Ongoing | Oral | Anti-Anemia |
| Kyntra Bio Inc Com (New) | Pamrevlumab - (ZEPHYRUS-2) | Idiopathic pulmonary fibrosis (IPF) | Phase 3 | Trial Discontinued | Intravenous | Respiratory |
| Kyntra Bio Inc Com (New) | SM-88, Gemcitabine, nab-paclitaxel, and pamrevlumab - (PanCAN_Precision Promise) | Metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 2/3 | Trial Discontinued | Oral Intravenous Intravenous Intravenous | Oncology |
| Kyntra Bio Inc Com (New) | FG-3246 | Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Enrollment Initiation | Oral | Oncology |
| Kyntra Bio Inc Com (New) | FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Kyntra Bio Inc Com (New) | Roxadustat - (WHITNEY) | Chemotherapy-induced anemia (CIA) | Phase 2 | Data Released | Oral | Hematology |
